@article{7a1d28cf0fbb46c9863e77ad3a2ee7b8,
title = "Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication",
abstract = "Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections.",
keywords = "2-Pyridinylmethylsulfinylbenzimidazoles, Anti-Bacterial Agents, Aza Compounds, Clarithromycin, Drug Combinations, Fluoroquinolones, Helicobacter Infections, Helicobacter pylori, Omeprazole, Patient Compliance, Quinolines, Treatment Outcome, 2-Pyridinylmethylsulfinylbenzimidazoles, Anti-Bacterial Agents, Aza Compounds, Clarithromycin, Drug Combinations, Fluoroquinolones, Helicobacter Infections, Helicobacter pylori, Omeprazole, Patient Compliance, Quinolines, Treatment Outcome",
author = "Veronica Ojetti and Zocco, {Maria Assunta} and Giovanni Cammarota and Antonio Gasbarrini and {Di Caro}, Simona and Filippo Cremonini and Marcello Candelli and Andrea Lupascu and F Bartolozzi and Ec Nista",
year = "2002",
language = "English",
volume = "16",
pages = "527--532",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Blackwell Science Limited:PO Box 88, Oxford OX2 0NE United Kingdom:011 44 1865 776868, 011 44 1865 206038, EMAIL: journals.cs@blacksci.co.uk, INTERNET: http://www.blackwell-science.com, Fax: 011 44 1865 721205",
}